This wiki has undergone a migration to Confluence found Here
CG WG Call Notes leading to 2015 May WGM
Contents
- 1 March 24, 2015 -- Weekly call
- 2 Proposed Agenda
- 3 Attendees
- 4 Draft Minutes
- 5 March 3, 2015 -- Weekly call
- 6 Proposed Agenda
- 7 Attendees
- 8 Draft Minutes
- 9 February 24, 2015 -- Weekly call
- 10 Proposed Agenda
- 11 Attendees
- 12 Draft Minutes
- 13 January 27, 2015 -- Weekly call
- 14 Proposed Agenda
- 15 Attendees
- 16 Draft Minutes
March 24, 2015 -- Weekly call
Proposed Agenda
- Discussion of FHIR profiles to Observation Resource
Attendees
- Amnon Shabo (Shvo), Mollie Ullman-Cullere, Bob Milius, Scott Botle, Larry Babb, Gil Alterovitz, Jami, Jeremy Warner, Siew Lam
Draft Minutes
- Larry asked what if we don’t submit to this ballot cycle
- Mollie: FHIR is about the 80:20 rule
- Scott and Mollie said it’s mainly for getting broader feedback, beyond our group
- Amnon:
- not sure if 80:20 rule applies to profiles
- if we submit, we have to add comments, disclaimers, indication that this attribute is just a stub to be evolving to structures in future releases
- Bob: what's a bundle of profiles?
- Larry: we need develop a bundle of resources like the bundles already on the FHIR ballot
- Mollie walked us through the proposed genetic profile over Observation and show a few samples
- Larry walked us through his comments on the sample Mollie showed:
- dbSNP id is problematic, for example the id used in the sample points to 4 different alleles
- use Sequence Ontology to identify DNA changes
- separate the first 19 attributes that describe the variant / allele and the rest of the attributes that describe other issues
- Mollie: interpretation was removed following Amnon's recommendation
- Vote: Bob, Jami: abstain, Amnon and Larry: negative, Mollie, Gil, Jeremy
March 3, 2015 -- Weekly call
Proposed Agenda
- Open discussion
Attendees
- Amnon Shabo (Shvo), Perry Mar, Mollie Ullman-Cullere, JD Nolen, Bob Freimuth, Bob Milius, Scott Botle, John Holt
Draft Minutes
- Discussed the bio-marker standardization effort
- how to get to 'common names' for mutations
- differences in testing platforms
- nomenclatures are problematic and it's better to get to the sequence level
February 24, 2015 -- Weekly call
Proposed Agenda
- Ballot reconciliation of the CG DIM 9/2014 ballot
Attendees
- Amnon Shabo (Shvo), Jonathan Holt, Grant Wood, Bob Milius, Perry Mar, Sue Lam, Mollie Ullman-Cullere, [the seventh participant - could you please add your name?]
Draft Minutes
- Amnon walked through his proposed dispositions & comments to the 9/2014 CG DIM ballot
- discussion was held and votes were recorded
- Perry Mar's comments on the Family Health History DIM were briefly discussed towards the end of the call but not concluded, so it was agreed to continue the discussion at a future call
- a few of the ballot comments on the relation between the DAM and the DIM triggered discussion on the best way forward in this regard
- Mollie suggested the DAM and the DIM will be maintained and balloted separately since they might be developed in different paces
- e.g. DAM will drive the DIM content and evolve at an earlier and faster pace particularly with rapidly evolving use cases
- Amnon said that it was already decided to merge the two documents, and while the DAM could exist without the DIM, the latter has to have the context that is provided by the DAM
- a possible way to handle the two documents is to have them reference each other, but that could lead to editorial integrity issues
- Mollie suggested the two documents be maintained and balloted separately, with more mature use cases and story boards needed to support the DIM content be created in summary fashion from the DAM. For instance the DAM may have 25 to 50 use cases showing the breadth of clinical paradigms (including very stable and emerging) to be considered by implementers, but the DIM would contain 3-4 stable use cases to support the information model.
- need to continue the DAM/DIM discussion but in any case the DIM will not be balloted in 5/2015; however, project database, ballot resolution, and publication of the clinical sequencing DAM are influenced by this decision.
- Mollie suggested the DAM and the DIM will be maintained and balloted separately since they might be developed in different paces
- Porting the DIM to a web-based tool
- Amnon briefly mentioned the porting of the DIM to a web-based UML editing tool that allows collaborative development of the model (it's available to everybody to view at https://repository.genmymodel.com/amnon.shvo/Clinical-Genomics-DIM)
- click on a class name on the right side bar to see the comment
- if you're interested to join the editing of the DIM, please drop a message to Amnon
January 27, 2015 -- Weekly call
Proposed Agenda
- Briefing on the San Antonio WGM meetings
Attendees
- Amnon Shabo (Shvo), Jonathan Holt, Grant Wood, Scott Bolte, Bob Milius, Larry Babb, Sue Lam
Draft Minutes
- Scott briefed on the San Antonio WGM meetings
- John:
- Genetic family history: gender vs. sex
- Modelling "Sequence"
- Larry: HGVS is not computable and quite ambiguous, and that's why it's important to pursue the "Sequence"modeling effort
- John: HGVS is actually interpretation and it's hard to get back to the raw data, based on which that HGVS expression was created
- Bob: rendering for the human viewing is case-specific (e.g., HLA) but the underlying structure should be unambiguous and common to all types of rendering